Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.

Table of Contents

• Bridging the ‘vast divide’: Mistrust, bias fuel racial disparities in lupus research Rob Volansky
• Avoiding implicit bias in rheumatologic care: The role of empathy Leonard H. Calabrese, DO
• Hydroxychloroquine use predicts lower risk for fatty liver disease in rheumatoid arthritis Jason Laday
• ‘Access should not be based on skin color’: The need for race-agnostic GCA care Rob Volansky
• Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks Erich Martin
• Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks Justin Cooper
• Booster COVID-19 vaccine dose protects against breakthrough infection in vasculitis Rob Volansky
• COVID-19 hospitalizations, deaths in patients with SAIRDs declined during omicron wave Erich Martin
• EULAR lowers acceptable threshold for daily prednisone dose in lupus maintenance Sara Kellner
• FDA testing finds hidden ingredients in products marketed for arthritis, pain Cassandra Jenkins
• Fourth COVID-19 vaccine dose reduces severe infection risk by 65% in patients with SARDs Rob Volansky
• Novel combination ABBV-599 improves lupus, offers ‘expanded coverage’ of pathology Rob Volansky
• ‘Now is the time for action’: ACR program seeks to overcome disparities in lupus care Rob Volansky
• Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014 Rob Volansky
• Oral brepocitinib fails to meet primary endpoint in phase 2 lupus study Jason Laday
• OTC birth control debut in 2024 ‘empowers’ patients with rheumatic diseases Rob Volansky
• Patients with rheumatoid arthritis report ‘many symptoms’ of long COVID prior to infection Rob Volansky
• Romosozumab superior to denosumab for improving spine bone mineral density at 12 months Rob Volansky
• SGLT2 inhibitors ‘substantially’ reduce gout risk in patients with type 2 diabetes Rob Volansky
• Single TLC599 injection superior to placebo for knee osteoarthritis pain over 24 weeks Rob Volansky
• Stay within hydroxychloroquine ‘therapeutic threshold’ to reduce active lupus, flare risk Robert Stott
• Telitacicept yields ‘really exciting’ results in rheumatoid arthritis structural damage Rob Volansky
• ‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis Rob Volansky
• Tofacitinib improves enthesitis in psoriatic arthritis regardless of baseline severity Erich Martin
• Updated ACR/EULAR APS criteria require positive antiphospholipid antibody test Erich Martin
• SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus Rob Volansky
• Novel nanobody izokibep demonstrates ‘high rates of response’ in psoriatic arthritis Rob Volansky